Exercise and the tumor microenvironment in non-small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study enrolls adults with early-stage non-small cell lung cancer who are scheduled for surgical resection and measures baseline physiologic fitness using VO2max, heart rate variability (HRV), and resting heart rate from clinical testing and wearable devices. Participants will undergo a targeted pre-operative exercise program (with or without medication) or usual care, and tumor tissue collected at resection will be analyzed for immune cell composition and molecular markers in the tumor microenvironment. Investigators will compare peri-operative and post-operative clinical outcomes, including complications and recovery, across patients with differing baseline physiologic states and after the exercise intervention. The aim is to link measurable physiologic metrics and pre-operative exercise to changes in tumor immune response and short-term surgical outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* lung cancer
* low risk for submaximal exercise testing in accordance with the risk stratification guidelines published by the American Heart Association and the American College of Sports Medicine (AHA/ACSM criteria).

Exclusion Criteria:

* younger than 18 years of age
* select a condition on the ACSM-AHA pre-exercise screening questionnaire indicating that physician approval is required prior to exercise
* body mass index of \>30 kg/m2
* waist girth of \>102cm for men and \>88cm for women
* have chronic/debilitating arthritis
* have been bedridden in the past three months
* have common illness (i.e. colds) within the past 6-weeks
* HIV
* hepatitis
* history of stroke
* major affective disorder
* autoimmune disease
* pregnancy or are breast-feeding
* history of severe anaphylactic reaction to an allergen
* present with more than one of the following CVD risk factors: family history of myocardial infarction, coronary revascularization, or sudden death before 55 years of age in father or other male first-degree relative or before 65 years of age in mother or other female first-degree relative

Where it's running

• University of Arizona Cancer Center
  Tucson, Arizona, United States Recruiting

Study contacts

• Principal investigator: Stephanie Worrell, MD — University of Arizona
• Study coordinator: Stephanie Worrell, MD
• Email: sworrell@arizona.edu
• Phone: 5206267806

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ivonescimab alone or with carboplatin/pemetrexed for advanced NSCLC with actionable alterations

  This trial tests if ivonescimab, alone or with chemotherapy, can shrink tumors in advanced NSCLC patients who have actionable genomic alterations after prior targeted therapies.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 2 other locations · NCT07405190

• Personalized exercise plan for cancer survivors

  This study tests a personalized, physician-guided exercise program for adults who have completed cancer treatment, to see if a safe, structured plan can be implemented in routine care.

  Recruiting Kaohsiung Medical University Chung-Ho Memorial Hospital · Kaohsiung, Taiwan · NCT07751783

• Abdominal pressure device to control breathing during stereotactic radiotherapy for peripheral non-small cell lung cancer

  This project tries an abdominal pressure device to reduce breathing-related tumor movement during stereotactic radiotherapy for people with solitary peripheral non-small cell lung cancer.

  Recruiting Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07561567

• Combining nutrition checks and muscle measurements to predict outcomes after lung cancer surgery

  This project will test whether combining nutrition tests and muscle scans can predict recovery, complications, and short-term outcomes in adults having lung cancer surgery.

  Recruiting Ondokuz Mayıs University · Samsun, Samsun · NCT07500376

• SL-28 for Advanced Solid Tumours

  A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.

  Recruiting Phase 1/2 Second Life Therapeutics · Sydney, New South Wales and 2 other locations · NCT07341737

• Phase II test of SKB571 for advanced non-small cell lung cancer

  This study will test SKB571 given alone in adults with advanced non-small cell lung cancer to see if it is safe and can shrink tumors.

  Recruiting Phase 2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Guangzhou and 1 other locations · NCT07230405

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.